Stage IIB Melanoma

Drug	Drug Name	Drug Description
DB09035	Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09037	Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.

Drug	Drug Name	Target	Type
DB09035	Nivolumab	Programmed cell death protein 1	target
DB09035	Nivolumab	Programmed cell death 1 ligand 1	target
DB09037	Pembrolizumab	Programmed cell death protein 1	target
DB09037	Pembrolizumab	Programmed cell death 1 ligand 1	target

Drug	Drug Name	Phase	Status	Count
DB17475	Incomplete Freund's adjuvant	0	Completed	1
DB15081	Melanoma antigen recognized by T-cells 1	0	Completed	1
DB06530	Resiquimod	0	Completed	1
DB14800	GP-100 antigen	2	Completed	1
DB17475	Incomplete Freund's adjuvant	2	Completed	1
DB11805	Saracatinib	2	Completed	1
DB00020	Sargramostim	2	Completed	1
DB16626	Tyrosinase	2	Completed	1
DB00020	Sargramostim	3	Withdrawn	1